IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival

Authors :: Florence Coulet
Laurence Baudrin
Martine Antoine
Jean-François Morère
Michèle Beau-Faller
Marie Wislez
Jacques Cadranel
Elizabeth Brambilla
Virginie Poulot
Marie Paule Lebitasy
Source :: Journal of Clinical Oncology. 26:8071-8071
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 8071 Background: A prospective multicentric trial evaluated gefitinib as 1st-line in non-resectable ADC-BAC. Tissue samples were collected to identify biomarkers associated with disease control, PF...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.disease
Disease control
body regions
Gefitinib
Internal medicine
Carcinoma
Medicine
Adenocarcinoma
business
medicine.drug
Predictive biomarker

Full Text Access

Tools